Adults and adolescents with hemophilia A or hemophilia B without inhibitors experienced significantly fewer bleeding episodes when using concizumab as a prophylactic (preventive) treatment compared with those who weren’t on any prophylaxis. That’s according to data from explorer8 (NCT04082429), an ongoing Phase 3 clinical study in which…

Hemophilia patients who received intensive factor VIII (FVIII) replacement therapy for better joint health were nearly five times more likely to see a reduction or complete resolution of synovial hypertrophy — swelling and thickening of the connective tissue that lines the inside of a joint — compared with those…

My oldest son, Julian, recently approached me and asked, “Dad, can you play this song for me on the piano? I have to post a singing audition tonight.” Panic filled my body. I responded, “Oh, Julian, this song has too many fast chord changes.” He walked away, trying to find…

A delayed diagnosis is common for people with acquired hemophilia A (AHA), according to a new study that found that it took more than a month to get a diagnosis after the first bleeding episode for about 1 in 3 patients. Despite these delays, all AHA patients in the…

As a woman with hemophilia, one of the greatest challenges I face is being believed. This challenge is multifaceted. First, I struggle to convince people that women can and do have hemophilia. Next, I have to explain that it’s possible for us to bleed like men with the…

Clotting proteins that are missing or are defective in hemophilia can directly affect the activity of cells responsible for maintaining bone health, a study found. The findings shed new light on why bone problems are a common issue among people with hemophilia, researchers said. The study, “…

This month, I attended One Drop, a “rare bleeding disorders consortium” hosted by Comprehensive Health Education Services (CHES) in Tampa, Florida. The event supported individuals and families with deficiencies of factor I, II, V, VII, X, XI, XIII as well as rare platelet disorders, such as Glanzmann thrombasthenia. Janet Brewer,…

Prophylactic replacement therapy to prevent bleeds was more cost-effective than on-demand treatment of active bleeds for children and adolescents in China with moderate or severe hemophilia A without inhibitors, a study reported. The superior cost-effectiveness of prophylaxis over on-demand treatment was mainly driven by the on-demand costs of treating…

Real-world use of the extended half-life factor replacement therapy Elocta (efmoroctocog alfa) was associated with better bleed control than standard half-life products among people with hemophilia A, according to findings from an observational study in Europe. Elocta, sold as Eloctate in the U.S., was also associated with fewer…

Hympavzi (marstacimab-hncq) may be available by prescription in the U.S. before the end of the year. The therapy was approved this month as a routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages 12 and older, with hemophilia A or…